338 related articles for article (PubMed ID: 31654702)
1. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
[TBL] [Abstract][Full Text] [Related]
2. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.
Ratelade J; Asavapanumas N; Ritchie AM; Wemlinger S; Bennett JL; Verkman AS
Acta Neuropathol; 2013 Nov; 126(5):699-709. PubMed ID: 23995423
[TBL] [Abstract][Full Text] [Related]
3. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
Tradtrantip L; Zhang H; Saadoun S; Phuan PW; Lam C; Papadopoulos MC; Bennett JL; Verkman AS
Ann Neurol; 2012 Mar; 71(3):314-22. PubMed ID: 22271321
[TBL] [Abstract][Full Text] [Related]
4. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity.
Duan T; Smith AJ; Verkman AS
Acta Neuropathol Commun; 2019 Jul; 7(1):112. PubMed ID: 31296268
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.
Tradtrantip L; Asavapanumas N; Verkman AS
Mol Pharmacol; 2013 Jun; 83(6):1268-75. PubMed ID: 23571414
[TBL] [Abstract][Full Text] [Related]
6. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.
Soltys J; Liu Y; Ritchie A; Wemlinger S; Schaller K; Schumann H; Owens GP; Bennett JL
J Clin Invest; 2019 Apr; 129(5):2000-2013. PubMed ID: 30958797
[TBL] [Abstract][Full Text] [Related]
7. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.
Ratelade J; Smith AJ; Verkman AS
Exp Neurol; 2014 May; 255():145-53. PubMed ID: 24636863
[TBL] [Abstract][Full Text] [Related]
8. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica.
Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS
Neuropharmacology; 2018 May; 133():345-353. PubMed ID: 29428821
[TBL] [Abstract][Full Text] [Related]
9. Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder.
Tradtrantip L; Yeaman MR; Verkman AS
Sci Rep; 2021 Nov; 11(1):21962. PubMed ID: 34753987
[TBL] [Abstract][Full Text] [Related]
10. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.
Crane JM; Lam C; Rossi A; Gupta T; Bennett JL; Verkman AS
J Biol Chem; 2011 May; 286(18):16516-24. PubMed ID: 21454592
[TBL] [Abstract][Full Text] [Related]
11. High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.
Miyazaki-Komine K; Takai Y; Huang P; Kusano-Arai O; Iwanari H; Misu T; Koda K; Mitomo K; Sakihama T; Toyama Y; Fujihara K; Hamakubo T; Yasui M; Abe Y
Br J Pharmacol; 2016 Jan; 173(1):103-14. PubMed ID: 26398585
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.
Tradtrantip L; Ratelade J; Zhang H; Verkman AS
Ann Neurol; 2013 Jan; 73(1):77-85. PubMed ID: 23055279
[TBL] [Abstract][Full Text] [Related]
13. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.
Phuan PW; Zhang H; Asavapanumas N; Leviten M; Rosenthal A; Tradtrantip L; Verkman AS
Acta Neuropathol; 2013 Jun; 125(6):829-40. PubMed ID: 23677375
[TBL] [Abstract][Full Text] [Related]
14. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.
Phuan PW; Ratelade J; Rossi A; Tradtrantip L; Verkman AS
J Biol Chem; 2012 Apr; 287(17):13829-39. PubMed ID: 22393049
[TBL] [Abstract][Full Text] [Related]
15. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
16. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4.
Phuan PW; Anderson MO; Tradtrantip L; Zhang H; Tan J; Lam C; Bennett JL; Verkman AS
J Biol Chem; 2012 Oct; 287(44):36837-44. PubMed ID: 22989877
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
Ratelade J; Zhang H; Saadoun S; Bennett JL; Papadopoulos MC; Verkman AS
Acta Neuropathol; 2012 Jun; 123(6):861-72. PubMed ID: 22526022
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
Tradtrantip L; Asavapanumas N; Verkman AS
Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
[No Abstract] [Full Text] [Related]
19. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.
Verkman AS; Phuan PW; Asavapanumas N; Tradtrantip L
Brain Pathol; 2013 Nov; 23(6):684-95. PubMed ID: 24118484
[TBL] [Abstract][Full Text] [Related]
20. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.
Tradtrantip L; Duan T; Yeaman MR; Verkman AS
J Neuroinflammation; 2019 Mar; 16(1):57. PubMed ID: 30851734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
